Stock INTERVACC AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Intervacc AB Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for Intervacc AB
15/05 Intervacc AB Announces Board Appointments CI
15/05 Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Sales per Business

SEK in Million2021Weight2022Weight Delta
Novel Veterinary Vaccines
100.0 %
5 100.0 % 10 100.0 % +84.77%

Sales per region

SEK in Million2021Weight2022Weight Delta
Sweden
100.0 %
5 100.0 % 10 100.0 % +84.77%

Managers

Managers TitleAgeSince
Jonas Sohlman CEO
 Chief Executive Officer - 21/23/21
Jan Persson DFI
 Director of Finance/CFO - 06/20/06
Andrew Waller CTO
 Chief Tech/Sci/R&D Officer - 11/20/11
Patrik Hellberg CIO
 Chief Investment Officer - -
Tim Wood LAW
 General Counsel - 01/18/01
Andreas Johansson PRN
 Corporate Officer/Principal 45 01/11/01

Members of the board

Members of the board TitleAgeSince
Boel Sundvall BRD
 Director/Board Member 65 01/23/01
Björn Magnus Sjöstrand CHM
 Chairman 56 -
Edwin Torr BRD
 Director/Board Member 63 -
Bengt Stefan Ståhl BRD
 Director/Board Member 63 01/09/01
Bengt Guss FOU
 Founder 66 01/01/01
Niels Holcke BRD
 Director/Board Member - 01/20/01
Michela de Carli BRD
 Director/Board Member - 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,736,264 59,198,500 ( 78.16 %) 0 78.16 %

Shareholders

NameEquities%Valuation
Swedbank Robur Fonder AB
6.773 %
5,129,802 6.773 % 2 M kr
Handelsbanken Fonder AB
6.029 %
4,565,935 6.029 % 2 M kr
Fjärde AP-fonden
4.951 %
3,750,000 4.951 % 1 M kr
Björn Magnus Sjöstrand
2.478 %
1,876,862 2.478 % 719 045 kr
H Bjorklund
2.010 %
1,522,647 2.010 % 583 341 kr
M Lundberg
2.009 %
1,521,648 2.009 % 582 959 kr
Aktia Fondbolag Ab
1.525 %
1,155,000 1.525 % 442 492 kr
Aktia Bank Plc (Investment Management)
1.525 %
1,155,000 1.525 % 442 492 kr
Kenneth Janzon
1.514 %
1,146,500 1.514 % 439 236 kr
Nordea Investment Management AB
1.496 %
1,132,944 1.496 % 434 042 kr

Company contact information

Intervacc AB

Västertorpsvägen 135 Hägersten

129 44, Stockholm

+46 8 12 01 06 00

http://www.intervacc.com
address Intervacc AB

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.99% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.01% 11TCr
BIONTECH SE Stock BioNTech SE
-3.07% 2.22TCr
ARGENX SE Stock argenx SE
-0.67% 2.13TCr
GENMAB A/S Stock Genmab A/S
-4.64% 1.88TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.90% 1.75TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 1.72TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.82% 1.41TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.05% 1.22TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. IVACC Stock
  4. Stock
  5. Company Intervacc AB